Using a new imaging agent to detect metastases in head and neck cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase I clinical trial evaluates the effectiveness of zirconium Zr 89 panitumumab combined with PET/CT imaging for diagnosing metastatic lesions in patients with head and neck squamous cell carcinoma. Participants will receive an infusion of 89Zr panitumumab and undergo PET/CT scans to assess the sensitivity and specificity of this investigational imaging agent compared to standard imaging methods. The study aims to improve the accuracy of detecting indeterminate metastatic lesions, which is crucial for determining appropriate treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>= 19 years
* Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck
* Subjects diagnosed with any T stage, any subsite within the head and neck. Subjects with recurrent disease or a new primary will be allowed
* Must have evidence of indeterminate metastatic squamous cell carcinoma (SCC) based on 18F-fluorodeoxyglucose (FDG)-PET/CT or Primary SCC with suspicious Lymph Nodes on CT prior to surgical removal
* Hemoglobin \>= 9gm/dL
* White blood cell count \> 3000/mm\^3
* Platelet count \>= 100,000/mm\^3
* Serum creatinine =\< 1.5 times upper reference range

Exclusion Criteria:

* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment
* History of infusion reactions to other monoclonal antibody therapies
* Pregnant (based on screening serum pregnancy test and day 0 urine pregnancy test administered before unlabeled panitumumab), or breastfeeding
* Magnesium or potassium lower than the normal institutional values
* Subjects receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
* Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
* Severe renal disease or anuria
* Known hypersensitivity to deferoxamine or any of its components

Where it's running

• Vanderbilt University/Ingram Cancer Center
  Nashville, Tennessee, United States Recruiting

Study contacts

• Principal investigator: Michael Topf, MD — Vanderbilt University/Ingram Cancer Center
• Study coordinator: Nicole Jones
• Email: nicole.l.jones@vumc.org
• Phone: 615-936-2807

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using [18F]NOTA-ABY030 PET/CT to clarify indeterminate head and neck squamous cell carcinoma lesions

  This trial will test whether the new PET imaging agent [18F]NOTA-ABY030 is safe and can better detect unclear primary or metastatic lesions in adults with head and neck squamous cell carcinoma.

  Recruiting Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07217028

• Remote hearing tests for patients with head and neck cancer receiving chemotherapy or radiation

  This study is testing if remote hearing tests can help patients with advanced head and neck cancer keep track of their hearing loss during chemotherapy or radiation, making it easier for those who live far away to participate.

  Recruiting Emory University · Atlanta, Georgia · NCT06662058

• Combination treatment for advanced head and neck cancer

  This study is testing a new combination treatment for people with advanced head and neck cancer to see if it can boost their immune response and help fight the disease.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06239220

• Using a radioactive drug to find cancer spread in head and neck patients

  This study is testing a new radioactive drug to see if it can help doctors find cancer spread in the lymph nodes of patients with head and neck cancer before surgery.

  Recruiting Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT05901545

• Using a new imaging method to locate head and neck cancer tumors

  This study is testing a new imaging method to see if it can better find and measure head and neck cancer tumors compared to the usual imaging technique.

  Recruiting Early Phase 1 University of Alabama at Birmingham · Birmingham, Alabama · NCT05183048

• Combination treatment for advanced head and neck cancer using radiation and immunotherapy

  This study is testing a new treatment for advanced head and neck cancer that combines a special type of radiation with an immunotherapy drug to see if it helps patients with hard-to-treat tumors.

  Recruiting at 2 sites Alpha Tau Medical LTD. · Jerusalem and 2 other locations · NCT05047094

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.